Article

Beaver Dam Eye Study shows marked change in impairment with age

An assessment of the cumulative incidence of changes in visualacuity for a 15-year period showed that, overall, 8% ofparticipants in the Beaver Dam Eye Study of age-related eyeconditions developed visual impairment, 1% developed severeimpairment, and 7% developed doubling of the visual angle.

An assessment of the cumulative incidence of changes in visual acuity for a 15-year period showed that, overall, 8% of participants in the Beaver Dam Eye Study of age-related eye conditions developed visual impairment, 1% developed severe impairment, and 7% developed doubling of the visual angle.

Data also showed a marked change in impairment with increasing age, said Barbara E.K. Klein, MD, MPH, professor of ophthalmology and visual sciences, University of Wisconsin School of Medicine and Public Health, Madison.

"People who were 75 and older at the baseline had about 12.8% times the odds of developing a visual impairment," Dr. Klein said. These individuals, born in the 1903-1907 cohort, were more likely than those born in later cohorts to develop visual impairment; the difference was statistically significant.

It is possible that advances in prevention and treatment of age-related diseases have influenced the differences between younger and older cohorts, Dr. Klein said. However, it may not be possible to analyze that hypothesis with the data from this study, particularly given the declining number of participants due to mortality.

Data also indicated that age-related macular degeneration was the most common cause of severe impairment, accounting for 52% of cases. Cataract and retinal vein occlusion were each responsible for 12% of incidents, while the rate of diabetic retinopathy was surprisingly low at 3%, Dr. Klein said.

The Beaver Dam Study was funded by the National Eye Institute to collect data on the prevalence and incidence of several age-related eye conditions. A private census identified approximately 6,000 individuals between the ages of 43 and 86 in the city and township of Beaver Dam, WI.

Approximately 5,000 of these individuals participated in baseline examinations between 1988 and 1990. At 5-, 10-, and 15-year intervals, all living members of this group were invited to follow-up examinations. Fifteen-year follow-up was completed in May 2005. Visual acuity was measured using Early Treatment for Diabetic Retinopathy Study protocols at all time points.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.